|Copyright 2006-2010 Abiant, Inc.
|Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030
Deerfield, ILLINOIS - - September 30, 2008 - - Abiant, Inc., a company specializing in advanced bio-
imaging to accelerate and improve drug development and disease diagnosis, has been selected to
be one of four Main Stage companies presenting at the Irish Angels Fall Investment Forum on October
2nd in Chicago.
The Fall Investment Forum provides an opportunity for members of Notre Dame’s IrishAngels network
and other accredited investors to review attractive investment opportunities that have an affiliation with
the University of Notre Dame community. Since the conference's inception in 2003, twenty-one
ventures have received more than $16 million dollars in angel investment, and several deals have
attracted significant venture funding and M&A interest.
Abiant, Inc. uses proprietary image analysis methods and software to provide a sensitive biomarker of
drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, can be used to accelerate or reduce risk of decision making
in both drug development and disease treatment. The Company’s focus areas include the central
nervous system, oncology, and inflammation. Further information can be found at www.abiant-
Forward Looking Statements
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
Abiant, Inc. Selected as Main Stage Presenter at Irish Angels Investment Forum